Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
On Tuesday, Celldex Therapeutics, Inc. (NASDAQ:CLDX) released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback